@article{article_1225685, title={Assessment Of Serum Cyanocobalamin Level And Importance In Patients With Hematological Malignancies}, journal={Turkish Journal of Clinics and Laboratory}, volume={14}, pages={270–273}, year={2023}, DOI={10.18663/tjcl.1225685}, author={Zeynelgil, Esra and Sağlam, Buğra and Asıl, Mehmet and Doğan, Özlem}, keywords={cyanocobalamin, CML, ALL, AML, Vitamin B12}, abstract={ABSTRACT Aim: In our study, we planned to investigate the effect of serum cyanocobalamin (Vitamin B12) levels at the time of diagnosis in patients with various hematological malignancies. Patients and Methods: Two hundred and one patients between 18-75 years old diagnosed with various hematological malignancies and 30 healthy controls applying to outpatient and inpatient clinics of Hematology Department in Necmettin Erbakan University Meram Faculty of Medicine between 2010-2014 years were included in the study. Demographic and clinical data and laboratory findings of the patients included in the study were recorded retrospectively. Results: A total of 231 patients, 132 men (57.1%) and 99 women (42.9%), were included in our study, of which 201 were patients and 30 were healthy controls. The mean serum vitamin B12 concentration of all patients was found as 344.9 ± 279.0 pg/mL. When vitamin B12 levels were analyzed according to diagnostic groups, it was found to be highest in CML (596.0 ± 428.3 pg / mL) and ALL (524.5 ± 442.6 pg / mL) patients and lowest in AML patients (240.9 ± 178, 0 pg / mL); the difference was statistically significant (p <0.001). Vitamin B12 levels of diagnostic groups were found to have no significant effect on survival. Conclusion: Cyanocobalamin levels were found to be high in patients with hematological malignancies, especially in CML patients. A high level of cyanocobalamin may be helpful in prediction of CML, however prospective studies are required to support this finding.}, number={2}, publisher={DNT Ortadoğu Yayıncılık A.Ş.}